Affinity-Tuned ErbB2 or EGFR Chimeric Antigen Receptor T Cells Exhibit an Increased Therapeutic Index against Tumors in Mice - Wikidata - wikimedia - TriplyDB

Affinity-Tuned ErbB2 or EGFR Chimeric Antigen Receptor T Cells Exhibit an Increased Therapeutic Index against Tumors in Mice

Affinity-Tuned ErbB2 or EGFR Chimeric Antigen Receptor T Cells Exhibit an Increased Therapeutic Index against Tumors in Mice

http://www.wikidata.org/entity/Q36028047

about

CAR models: next-generation CAR modifications for enhanced T-cell function New Strategies for the Treatment of Solid Tumors with CAR-T Cells Chimeric Antigen Receptor-Modified T Cells for Solid Tumors: Challenges and Prospects Chimeric Antigen Receptors Modified T-Cells for Cancer Therapy CAR T Cell Therapy: A Game Changer in Cancer Treatment Immune Responses to Epidermal Growth Factor Receptor (EGFR) and Their Application for Cancer Treatment Structural basis for cancer immunotherapy by the first-in-class checkpoint inhibitor ipilimumab Chimeric Antigen Receptor-Engineered NK-92 Cells: An Off-the-Shelf Cellular Therapeutic for Targeted Elimination of Cancer Cells and Induction of Protective Antitumor Immunity Emerging immunotherapeutics in adenocarcinomas: A focus on CAR-T cells Novel T cells with improved in vivo anti-tumor activity generated by RNA electroporation.An oxygen sensitive self-decision making engineered CAR T-cell.Masked Chimeric Antigen Receptor for Tumor-Specific Activation.Bispecific antibodies and CARs: generalized immunotherapeutics harnessing T cell redirection.Smart CARS: optimized development of a chimeric antigen receptor (CAR) T cell targeting epidermal growth factor receptor variant III (EGFRvIII) for glioblastoma CAR-T cell therapy in gastrointestinal tumors and hepatic carcinoma: From bench to bedside.New development in CAR-T cell therapy.Adoptive T Cell Therapies: A Comparison of T Cell Receptors and Chimeric Antigen Receptors Phase I study of chimeric antigen receptor modified T cells in treating HER2-positive advanced biliary tract cancers and pancreatic cancers.Tumor Antigen and Receptor Densities Regulate Efficacy of a Chimeric Antigen Receptor Targeting Anaplastic Lymphoma Kinase.Engineering T Cells with Customized Therapeutic Response Programs Using Synthetic Notch Receptors.Treatment of solid tumors with chimeric antigen receptor-engineered T cells: current status and future prospects.Driving gene-engineered T cell immunotherapy of cancer.Spotlight on chimeric antigen receptor engineered T cell research and clinical trials in China.Engineered T cells: the promise and challenges of cancer immunotherapy.How Chimeric Antigen Receptor Design Affects Adoptive T Cell Therapy.T-lymphocyte homing: an underappreciated yet critical hurdle for successful cancer immunotherapy.Shared target antigens on cancer cells and tissue stem cells: go or no-go for CAR T cells?From therapeutic antibodies to chimeric antigen receptors (CARs): making better CARs based on antigen-binding domain.Chimeric antigen receptors for treatment of glioblastoma: a practical review of challenges and ways to overcome them.Engineering Therapeutic T Cells: From Synthetic Biology to Clinical Trials.Tumor-targeting domains for chimeric antigen receptor T cells.The Principles of Engineering Immune Cells to Treat Cancer.Current modalities in cancer immunotherapy: Immunomodulatory antibodies, CARs and vaccines.CARs: Synthetic Immunoreceptors for Cancer Therapy and Beyond.Engineering Chimeric Antigen Receptor T-Cells for Racing in Solid Tumors: Don't Forget the Fuel Increasing the safety and efficacy of chimeric antigen receptor T cell therapy.Current status and perspectives of chimeric antigen receptor modified T cells for cancer treatment.Hit-and-run programming of therapeutic cytoreagents using mRNA nanocarriers.Therapeutic T cell engineering.Mesothelin-targeting chimeric antigen receptor-modified T cells by piggyBac transposon system suppress the growth of bile duct carcinoma.

P2860

Q26745600-0720F1C9-282B-4AF1-8BA6-CA18C7D33953 Q26748500-D9516CBC-E7FE-4CA8-9F17-FBE0701F6867 Q26753082-48DFB357-8A34-4E6A-9933-EE44E61B4B80 Q26773309-A6BE53F4-28C0-4AE4-B794-2FDECEBC017D Q26822769-EBBC5778-9E90-4949-9B65-0FA6E5A46145 Q28069424-D5105C88-E79C-47C4-9DB7-14F3FE7B67A1 Q30274619-8B2209D9-8200-480C-AA71-20C35A14DC21 Q33700795-477E8C0A-6855-4B52-AEE1-434CE370B97E Q33833475-0A5165FE-058F-4F7F-82F0-9B8813B7E2CA Q33874986-2FB7C0E9-710B-4785-9158-9E5FB039843A Q34047851-13F6AE9E-E06C-4251-B8C9-0062871A00C5 Q34047878-5C63F3DF-9475-44CD-AAC4-DA3829154AD6 Q34517676-4F84B851-5AAE-4AF6-8EBD-D27731DB2627 Q36474226-394682C7-3C28-45A7-8517-8A9E576B2F8E Q37559401-6E3BC9B9-A7E7-4F21-B6C7-9C1913F5BA5D Q37658246-6D4DCF85-958E-49F2-9FC0-DB03B7479E3A Q38603686-8480F4AE-EF05-4101-8419-AEFE5681DBC6 Q38677904-F21DFC1A-8E36-45C1-94D4-EADED88E5E60 Q38694036-54342153-3446-40D4-957E-16463D320E6F Q38742968-F9B55488-9334-4B9D-8187-4A484C3FF1DE Q38770555-8DD7C337-4498-417A-8995-59243772AF6C Q38777742-94B195CC-8F60-4AB8-8062-3492ED15B778 Q38786626-B4426BCE-6B9B-422B-9BB7-5BA48BBAEB59 Q38828829-4795E83B-53CA-45BB-9CB3-C35680594396 Q38830813-D2C6E86C-BF09-474F-BDE8-6992FF65E892 Q38873974-9458AA30-B310-4806-8124-D6CB527A899E Q38933510-7CD94227-2323-45C1-806F-ADDB9087A95A Q38951943-CC21E82B-69C5-46FE-9AE7-A0F58170B798 Q38987239-83BE119E-BA0F-40BB-81E2-9F01C79F4D31 Q39037477-C6634ECB-9EC2-4C77-ACD6-FC49AF9AF92F Q39045535-201B3504-D0CD-46DB-84B0-F1FF2924934C Q39130457-2635DB66-2455-4317-8BDA-3B123DDA0510 Q39189908-01EC0C53-59AC-405D-9B60-C3BF1CAACE44 Q39246685-445CBAB8-13E5-4120-80E4-1CF1075B1FA3 Q39249589-516D9433-D008-4377-853B-4813734A390B Q39256918-C2104C75-872C-4DDF-AD5F-5606E4CFA293 Q39280002-211D6934-02C8-4061-BB19-56FB4106EA87 Q40064246-DB6A5799-9BD5-42E0-8999-60536A4EAB8C Q40199809-0168F2A0-860F-4586-B212-9B8A6182931F Q40256333-30050E87-0D78-4877-A2D1-5678AD6C233F

P2860

Affinity-Tuned ErbB2 or EGFR Chimeric Antigen Receptor T Cells Exhibit an Increased Therapeutic Index against Tumors in Mice

http://www.wikidata.org/entity/Q36028047

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Affinity-Tuned ErbB2 or EGFR C ...... c Index against Tumors in Mice

@ast

Affinity-Tuned ErbB2 or EGFR C ...... c Index against Tumors in Mice

@en

type

label

Affinity-Tuned ErbB2 or EGFR C ...... c Index against Tumors in Mice

@ast

Affinity-Tuned ErbB2 or EGFR C ...... c Index against Tumors in Mice

@en

prefLabel

Affinity-Tuned ErbB2 or EGFR C ...... c Index against Tumors in Mice

@ast

Affinity-Tuned ErbB2 or EGFR C ...... c Index against Tumors in Mice

@en

P1433

Q36028047-556B248C-B97E-4B45-852F-C7B006678F5F

P1476

Q36028047-017968A1-3DD6-4578-8542-606CE225E46A

P2093

Q36028047-011518B5-8D95-43DD-9FA9-0B7992B1F073

Q36028047-1D1999D5-2EFB-4D4D-956C-51F3FA0967BC

Q36028047-2FFEFC4B-C2B9-456B-BA97-F957EAEDEE47

Q36028047-31A023FE-53A9-4166-9C89-CBBD1D94A8CA

Q36028047-395164A2-2871-4DA3-A5C5-77D5822C33A0

Q36028047-480D4184-B1F3-4DE1-A23C-B7A4FBC27EC8

Q36028047-4ED4F9C4-A5E9-473E-A7C8-02260E7C53A1

Q36028047-5FE0AFA1-F779-4786-93F1-9BFCBD8ABF7C

Q36028047-6547E884-999E-46AA-8BEE-7F8E9D5DB6B5

Q36028047-7B35D130-8AA5-4311-8A42-AE1D9EA36C81

P2860

Q36028047-171B6000-4C01-4FAA-B5E3-A73ECE397E06

Q36028047-1C59E3B2-6228-4315-A06E-565C397E7C9A

Q36028047-227C9A03-F991-4BD7-8162-B23A56530AC1

Q36028047-362475BF-87D2-466E-9EB0-71077B0642F0

Q36028047-39360AAE-8A10-4EDF-B738-A9407C6915CA

Q36028047-47BD696D-03DF-4327-91E0-A71B2884A46F

Q36028047-4F172DA6-90EA-48D1-A3AD-249A53243721

Q36028047-590E4AC5-8E52-4602-83E2-E970311B0B97

Q36028047-5AE5F9DA-5EDA-42E7-8FE0-E496EDD2A1BB

Q36028047-5C21367F-28D0-4CA9-A02E-032188749E6F

P304

Q36028047-AE96FB75-25BD-42DE-99D8-D30ACF78EC69

P31

Q36028047-63F8C040-EEA2-4E56-9697-15DBEAB402D4

P356

Q36028047-F2C8F8E0-9899-488F-A8AC-B0A911C17011

P407

Q36028047-CB22E1B5-5D05-4523-A232-63F2A280D67C

P433

Q36028047-5FAE97A4-D59C-48D7-93C0-04C016046EA1

P478

Q36028047-61D1FB2B-9D44-400F-B45D-8D9C275F5004

P50

Q36028047-8460B0D2-9F01-4EC3-ADA3-E9331B22A15F

P577

Q36028047-1E285D53-4BA2-4C14-8B0A-AE760C68899A

P698

Q36028047-51F599C2-CE8E-41B1-AFB2-77F3D9A5CC4B

P932

Q36028047-9E8FA28E-8008-4D8E-B2A6-9EEB89634CEF

P356

0008-5472.CAN-15-0159

P1433

Cancer Research

P1476

Affinity-Tuned ErbB2 or EGFR C ...... c Index against Tumors in Mice

@en

P2093

Andreas Loew

http://www.w3.org/2001/XMLSchema#string

Brian Granda

http://www.w3.org/2001/XMLSchema#string

Carl H June

http://www.w3.org/2001/XMLSchema#string

Chongyun Fang

http://www.w3.org/2001/XMLSchema#string

Devvora Olalere

http://www.w3.org/2001/XMLSchema#string

Edward C Pequignot

http://www.w3.org/2001/XMLSchema#string

Li Zhou

http://www.w3.org/2001/XMLSchema#string

Melissa Ramones

http://www.w3.org/2001/XMLSchema#string

Na Li

http://www.w3.org/2001/XMLSchema#string

Regina M Young

http://www.w3.org/2001/XMLSchema#string

P2860

Humanization of an anti-p185HER2 antibody for human cancer therapy

Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer

Inducible apoptosis as a safety switch for adoptive cell therapy

CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia

Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2

Selection of cell binding and internalizing epidermal growth factor receptor antibodies from a phage display library.

Impact of single-chain Fv antibody fragment affinity on nanoparticle targeting of epidermal growth factor receptor-expressing tumor cells.

High-affinity TCRs generated by phage display provide CD4+ T cells with the ability to recognize and kill tumor cell lines.

T cell receptor binding kinetics required for T cell activation depend on the density of cognate ligand on the antigen-presenting cell.

P304

3596-3607

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/0008-5472.CAN-15-0159

http://www.w3.org/2001/XMLSchema#string

P407

P433

17

http://www.w3.org/2001/XMLSchema#string

P478

75

http://www.w3.org/2001/XMLSchema#string

P50

Alexandria P Cogdill

P577

2015-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26330166

http://www.w3.org/2001/XMLSchema#string

P932

4560113

http://www.w3.org/2001/XMLSchema#string